Impact Of Excitatory Amino Acid Neurotransmitters As Clinical Probe To Assess Gonadotropin Releasing-Hormone Neuronal Function

Abstract

Objective: To evaluate how peripheral glutamate injection affects human gonadotropins and testosterone production

Methodology:

During 6^th October to 30^th December 2023, an experimental investigation was conducted. Intravenous doses of 0, 5, 10, or 20 mg/kg BW of monosodium glutamate (MSG) were given at random to adult healthy men (n = 4 each dose). Sequential blood samples were taken at 30-minute intervals for one hour prior to and three hours following the administration of MSG. Specific enzyme immunoassays (EIA) or immunoenzymatic assays (IEMA) were used to assess testosterone, follicle stimulating hormone (FSH), and luteinizing hormone (LH) levels in serum. By using a t-test to compare the mean hormone concentrations recorded before and after the medication delivery times, the effectiveness of MSG was assessed.

Results:

When 5 mg and 10 mg doses of MSG were administered along with saline (0 mg MSG), the post-MSG LH concentration increased (P<0.05) in comparison to the mean pre-MSG levels of LH in the serum. The levels of the serum LH was not impacted by the 20 mg dose of MSG. All MSG injection dosages resulted in a notable rise in mean levels of serum FSH. FSH levels remained unchanged in those who received 0 mg of MSG. Serum testosterone levels remained unchanged by MSG dosages of 0, 5, and 10 mg. However, blood testosterone levels decreased (P < 0.05) in response to a 20 mg dosage of MSG.

Conclusion:

The current findings show for the first time that gonadotropin secretion is stimulated by peripheral MSG treatment. These results suggest that glutamate is involved in the regulation of gonadotropin release.